Compare Automatic Data Processing Inc (ADP) vs Pfizer Inc (PFE) Price & Performance

ADP trades at $271.32, down 0.8% for the day, with strong technical momentum showing bullish moving averages and key support at $269. The company demonstrates robust fundamentals with consistent earnings beats, 20.11% net margins, and 72.24% ROE. Recent Q4 2026 results showed 7% revenue growth and 17% EPS growth, driving positive analyst sentiment despite elevated valuation multiples.

Outlook remains positive with a $280.50 consensus price target offering 3.4% upside potential. Key opportunities include margin expansion and dividend stability, while risks center on high valuation sensitivity and labor market volatility affecting ADP's payroll processing business. The stock presents a quality growth opportunity with disciplined risk management required.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.